A new study shows that teenagers who consumed marijuana before 15 were more likely to seek physical or mental medical care than their counterparts.
The FDA’s effort to expedite reviews for drugs in line with the Trump administration’s priorities was greeted warmly by a ...
Jo Varshney, PhD, DVM, discusses how artificial intelligence–powered simulations speed drug approvals and reduce clinical ...
A new Gallup poll indicates that the obesity rate among U.S. adults has declined over the past three years as the number of ...
Once those prices are set, most large government programs that cover prescription drugs pay prices that are tied to ...
FDA issues new guidance aimed at speeding biosimilar time to market and lower costs, and more in the latest National Advocacy ...
The draft guidance, which is touted as a way to reduce the cost and time-associated burden of biosimilar development, has ...
Proteins play a key role not only in the body, but also in medicine: they either serve as active ingredients, such as enzymes ...
PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy ...
The FDA today unveiled a plan to accelerate development of biosimilars in hopes of significantly reducing drug costs in the United States.The agency issued draft guidance that would simplify the study ...
By emphasizing analytical studies instead of routine clinical trials, the FDA signals its intent to reduce the cost (often estimated at $100 million to $300 million) and time (typically 6–9 years) ...
In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback